Foamix stock bub­bles high­er on lat­est ac­ne PhI­II; Con­cen­tric Anal­gesic gets an FDA 'break­through'

→ Shares of Foamix Ther­a­peu­tics $FOMX soared Tues­day night on news that their third Phase III study of a new ac­ne med suc­ceed­ed in de­liv­er­ing sig­nif­i­cant ben­e­fits. The num­bers may not be over­whelm­ing, with in­ves­ti­ga­tors not­ing that a “mean re­duc­tion in in­flam­ma­to­ry le­sion count at Week 12 rel­a­tive to base­line was -16.93 for the FMX101 treat­ment group and -13.40 for the ve­hi­cle treat­ment group (p<0.0001).” But in­vestors loved it. Shares rock­et­ed up more than 50% in af­ter-mar­ket trad­ing and were still up 23% in ear­ly morn­ing trad­ing Wednes­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER